This New Oral Vaccine Could Slash Colorectal Cancer Rates by 50%! Are You at Risk?

Groundbreaking research from a team at Stony Brook University is exploring a novel approach in the fight against colorectal cancer, one of the deadliest forms of cancer worldwide. The study, led by immunologist Brian Sheridan, reveals how a modified version of the bacterium Listeria monocytogenes can serve as an oral vaccine to stimulate the immune system directly in the gut, generating anti-tumor cells where colorectal cancer typically originates.

Colorectal cancer is projected to result in over 150,000 new cases and more than 55,000 deaths in the United States by 2026, according to the American Cancer Society. Despite advancements in cancer immunotherapy—treatments that harness the body’s immune system to fight cancer—most colorectal cancers remain largely unresponsive to existing immunotherapies. This research aims to change that dynamic.

Listeria, while known for causing infection, has shown promise in cancer treatment and is currently undergoing pre-clinical and clinical trials for various cancer types, including colorectal cancer. Unlike previous approaches that administered Listeria via intravenous methods, this innovative study utilizes an oral delivery system, which provokes a robust anti-tumor CD8 T cell response specifically within gastrointestinal tissues. This targeted method focuses on the very environment where colorectal cancer develops, thus enhancing the vaccine's efficacy.

In a murine model of colorectal cancer, the research team engineered a highly attenuated strain of Listeria by removing specific virulence genes while still allowing it to engage with the intestinal immune system. This strategic modification enabled the generation of an anti-tumor response without the risk of causing Listeriosis, a serious illness.

The results from this study are promising. The vaccine effectively remained localized within intestinal tissues, showing no significant spread to other organs or adverse side effects, such as weight loss. This localized action ensures that the immune response is directed exactly where it's needed, targeting colorectal cancer cells while minimizing damage to healthy tissues.

“The clinical significance of our laboratory findings is underscored by the vaccine performance in treating established tumors,” says Sheridan. “While this vaccine alone initially curtailed local tumor growth, its true potential was revealed when combined with existing immune checkpoint inhibitors.”

The combination of this oral immunization with immune checkpoint inhibitors led to dramatic tumor control in the mouse models, suggesting that this method could activate the immune system in tumors that have previously resisted standard immune therapies. Moreover, this approach successfully induced the accumulation of tumor-specific CD8 T cells in the tumor environment. These specialized immune cells not only remain stationed in the gut but also provide immediate and enduring protection against cancer cells—results that weren't replicated when using the vaccine or immune checkpoint inhibitors alone.

Ultimately, Sheridan emphasizes that this strategy could significantly improve the prognosis for patients with advanced or metastatic colorectal cancer, particularly those with limited therapeutic options. He believes this research could pave the way for a new generation of cancer vaccines that might not only prevent cancer onset but also enhance the effectiveness of existing immunotherapy approaches.

This study received funding from several sources, including the Department of Defense, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), the Research Foundation for the State University of New York, and various charitable foundations. As the research progresses, it holds the potential to redefine therapeutic strategies for one of the most challenging cancers to treat.